清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

医学 肝细胞癌 核医学 新辅助治疗 肝切除术 实体瘤疗效评价标准 放射科 进行性疾病 内科学 化疗 癌症 外科 乳腺癌 切除术
作者
Qiang Li,Xiaolan Wang,Deju Li,Yulong Liu,Kangshou Liu,Junjie Liang,Jian Sun,Quan Jiang,Jiexing Li,Zhilong Liu,Jian Gong,Leyang Xiang,Zhidong Jia,Zhiwei Chen,Mingrong Cao,Yuchuan Jiang
出处
期刊:Journal of Visualized Experiments [MyJOVE]
卷期号: (207) 被引量:2
标识
DOI:10.3791/66407
摘要

This study showcases a comprehensive treatment protocol for high-risk hepatocellular carcinoma (HCC) patients, focusing on the combined use of Y-90 transarterial radioembolization (TARE) and Programmed Cell Death-1 (PD-1) inhibitors as neoadjuvant therapy. Highlighted through a case report, it offers a step-by-step reference for similar therapeutic interventions. A retrospective analysis was conducted on a patient who underwent hepatectomy following Y-90 TARE and PD-1 inhibitor treatment. Key demographic and clinical details were recorded at admission to guide therapy selection. Y-90 TARE suitability and dosage calculation were based on Technetium-99m (Tc-99m) macroaggregated albumin (MAA) perfusion mapping tests. Lesion coverage by Y-90 microspheres was confirmed through single photon emission computed tomography/computed tomography (SPECT/CT) fusion imaging, and adverse reactions and follow-up outcomes were meticulously documented. The patient, with a 7.2 cm HCC in the right hepatic lobe (T1bN0M0, BCLC A, CNLC Ib) and an initial alpha-fetoprotein (AFP) level of 66,840 ng/mL, opted for Y-90 TARE due to high recurrence risk and initial surgery refusal. The therapy's parameters, including the lung shunting fraction (LSF) and non-tumor ratio (TNR), were within therapeutic limits. A total of 1.36 GBq Y-90 was administered. At 1 month post-therapy, the tumor shrank to 6 cm with partial necrosis, and AFP levels dropped to 21,155 ng/mL, remaining stable for 3 months. After 3 months, PD-1 inhibitor treatment led to further tumor reduction to 4 cm and AFP decrease to 1.84 ng/mL. The patient then underwent hepatectomy; histopathology confirmed complete tumor necrosis. At 12 months post-surgery, no tumor recurrence or metastasis was observed in follow-up sessions. This protocol demonstrates the effective combination of Y-90 TARE and PD-1 inhibitor as a bridging strategy to surgery for HCC patients at high recurrence risk, providing a practical guide for implementing this approach.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
chewenbo完成签到,获得积分10
3秒前
冷静冰萍完成签到 ,获得积分10
35秒前
葛力完成签到,获得积分10
46秒前
奈何完成签到 ,获得积分10
48秒前
CATH完成签到 ,获得积分10
1分钟前
一个小胖子完成签到,获得积分10
1分钟前
Kao应助科研通管家采纳,获得10
1分钟前
Kao应助科研通管家采纳,获得10
1分钟前
Kao应助科研通管家采纳,获得10
1分钟前
披着羊皮的狼完成签到 ,获得积分0
1分钟前
1分钟前
花海发布了新的文献求助10
2分钟前
月亮啊完成签到 ,获得积分10
2分钟前
上官若男应助花海采纳,获得10
2分钟前
SQL完成签到 ,获得积分10
2分钟前
Kao应助chewenbo采纳,获得10
2分钟前
3分钟前
蓝意完成签到,获得积分0
3分钟前
Kao应助科研通管家采纳,获得10
3分钟前
Kao应助科研通管家采纳,获得10
3分钟前
神一样的鸟完成签到 ,获得积分10
4分钟前
锂电说完成签到 ,获得积分10
4分钟前
Tttttttt完成签到,获得积分10
4分钟前
华仔应助青禾纪时采纳,获得10
4分钟前
糟糕的翅膀完成签到,获得积分10
4分钟前
emchavezangel完成签到,获得积分10
4分钟前
流云完成签到,获得积分10
4分钟前
4分钟前
Zhaoyuemeng发布了新的文献求助10
5分钟前
包子牛奶完成签到,获得积分10
5分钟前
睡不醒完成签到 ,获得积分10
5分钟前
Kao应助科研通管家采纳,获得10
5分钟前
Kao应助科研通管家采纳,获得10
5分钟前
Kao应助科研通管家采纳,获得10
5分钟前
Kao应助科研通管家采纳,获得10
5分钟前
5分钟前
青禾纪时发布了新的文献求助10
5分钟前
5分钟前
Jamal完成签到,获得积分10
5分钟前
AN发布了新的文献求助10
5分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Nondestructive Testing Handbook: Vol. 4, Thermal and Infrared Testing (IR), 4th ed 800
作者名:Kristopher P. Plain,悉尼大学的,目前只能查到其四篇论文,想找到其博士论文 590
Évora na Idade Média 555
Soil mites of the family Rhagidiidae (Actinedida: Eupodoidea). Morphology, Systematics, Ecology 520
Matrix Methods in Data Mining and Pattern Recognition Second Edition 510
Radical Reactions 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7363263
求助须知:如何正确求助?哪些是违规求助? 8972375
关于积分的说明 19071788
捐赠科研通 7008600
什么是DOI,文献DOI怎么找? 3223710
关于科研通互助平台的介绍 2387397
邀请新用户注册赠送积分活动 2204492